This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

(GCIG/JGOG 3017) CCC-1 Version 2.4-25th February 2008

  • Research type

    Research Study

  • Full title

    Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P)Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as First Line Chemotherapy for Clear Cell Carcinoma of the Ovary

  • Sponsor organisation

    Greater Glasgow Health Board

  • Eudract number

    2007-007849-13

  • ISRCTN Number

    0

  • Clinicaltrials.gov Identifier

    0

  • Research summary

    Clear cell cancer of the ovary is a rare type of ovarian cancer. There is evidence that clear cell cancers do not respond as well as other ovarian cancers to the standard therapy of Carboplatin and Paclitaxel generally given for ovarian cancer.This trial is the result of a consensus between major research groups in ovarian cancer worldwide which concluded a study to investigate better treatments for this disease was required. The purpose of the trial is to compare the effectiveness and side effects of two chemotherapy regimens (standard arm Carboplatin and Paclitaxel versus experimental arm Irinotecan and Cisplatin). The results from a smaller randomised trial conducted using the same regimens have been encouraging, which has led to the development of this trial. <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="padding-right: 9pt; padding-left: 9pt; padding-bottom: 0cm; padding-top: 0cm"> </td> </tr> </tbody></table> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="padding-right: 9pt; padding-left: 9pt; padding-bottom: 0cm; padding-top: 0cm"> </td> </tr> </tbody></table>

  • REC name

    North West - Haydock Research Ethics Committee

  • REC reference

    08/H1010/100

  • Date of REC Opinion

    30 Jan 2009

  • REC opinion

    Further Information Favourable Opinion